DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides.

Author(s): Barter P

Affiliation(s): The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia. p.barter@hri.org.au

Publication date & source: 2006-08, Atheroscler Suppl., 7(4):17-21. Epub 2006 Jul 7.

Publication type: Review

Treatment with statins reduces coronary risk In all people but do not remove the risk associated with a low HDL-C or with other features of the metabolic syndrome such as an elevated level of plasma triglyceride or with a high BMI. Treatment with a fibrate such as gemfibrozil (a PPAR alpha agonist) has been shown to be especially effective in people with low HDL-C and other features of the metabolic syndrome. Potential beneficial effects of the combination of a statin and an agent with PPAR alpha activity in patients with type 2 diabetes is currently being addressed in the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.

Page last updated: 2007-02-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017